Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer

Clinical Colorectal Cancer

Volumn 13, Issue 3, 2014, Pages 164-171

  Morris, Van ^a   Overman, Michael J ^a   Jiang, Zhi Qin ^a   Garrett, Christopher ^a   Agarwal, Shweta ^a   Eng, Cathy ^a   Kee, Bryan ^a   Fogelman, David ^a   Dasari, Arvind ^a   Wolff, Robert ^a   Maru, Dipen ^a   Kopetz, Scott ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarker; Chemotherapy; Mutation; Prognosis; Recurrence

Indexed keywords

B RAF KINASE; FLUOROURACIL; IRINOTECAN; MICROSATELLITE DNA; OXALIPLATIN; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; CAMPTOTHECIN; CETUXIMAB; MONOCLONAL ANTIBODY; PANITUMUMAB; PLATINUM COMPLEX; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; STANDARD; SYSTEMIC THERAPY; ANALOGS AND DERIVATIVES; CANCER STAGING; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPH NODE METASTASIS; METASTASIS RESECTION; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; PATHOLOGY; PERITONEAL NEOPLASMS; SECONDARY; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CAMPTOTHECIN; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; METASTASECTOMY; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; SURVIVAL RATE;

EID: 84908219463     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2014.06.001     Document Type: Article

References (35)

1. R. Siegel, C. DeSantis, and K. Virgo Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 62 2012 220 241
2. B. Nordlinger, H. Sorbye, and B. Glimelius Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Lancet 371 2008 1007 1016
3. T. Andre, C. Louvet, and F. Maindrault-Goebel CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR Eur J Cancer 35 1999 1343 1347
4. C.S. Fuchs, J. Marshall, and E. Mitchell Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study J Clin Oncol 25 2007 4779 4786
5. F. Kabbinavar, H.I. Hurwitz, and L. Fehrenbacher Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 2003 60 65
6. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
7. Y. Fong, A.M. Cohen, and J.G. Fortner Liver resection for colorectal metastases J Clin Oncol 15 1997 938 946
8. M.A. Choti, J.V. Sitzmann, and M.F. Tiburi Trends in long-term survival following liver resection for hepatic colorectal metastases Ann Surg 235 2002 759 766
9. S. Kopetz, G.J. Chang, and M.J. Overman Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy J Clin Oncol 27 2009 3677 3683
10. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
11. J.Y. Douillard, K.S. Oliner, and S. Siena Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 2013 1023 1034
12. H. Davies, G.R. Bignell, and C. Cox Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
13. J. Tie, P. Gibbs, and L. Lipton Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation Int J Cancer 128 2011 2075 2084
14. T. Yokota, T. Ura, and N. Shibata BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer Br J Cancer 104 2011 856 862
15. T.J. Price, J.E. Hardingham, and C.K. Lee Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer J Clin Oncol 29 2011 2675 2682
16. S. Ogino, K. Shima, and J.A. Meyerhardt Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803 Clin Cancer Res 18 2012 890 900
17. P.T. Wan, M.J. Garnett, and S.M. Roe Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
18. C. Pritchard, L. Carragher, and V. Aldridge Mouse models for BRAF-induced cancers Biochem Soc Trans 35 2007 1329 1333
19. S. Kopetz, J. Desai, and E. Chan PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors J Clin Oncol 28 suppl 15 2010 abstract3534
20. P.B. Chapman, A. Hauschild, and C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
21. J.A. Sosman, K.B. Kim, and L. Schuchter Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
22. S. Enge, D. Byrd, C. Comptom, A. Fritz, F. Green, and A. Trotti Cancer Staging Manual 7th ed. 2010 Springer New York
23. B. Tran, S. Kopetz, and J. Tie Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer Cancer 117 2011 4623 4632
24. W.S. Samowitz, C. Sweeney, and J. Herrick Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers Cancer Res 65 2005 6063 6069
25. J. Tol, I.D. Nagtegaal, and C.J. Punt BRAF mutation in metastatic colorectal cancer N Engl J Med 361 2009 98 99
26. J. Souglakos, J. Philips, and R. Wang Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer Br J Cancer 101 2009 465 472
27. T.S. Maughan, R.A. Adams, and C.G. Smith Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 2011 2103 2114
28. F. Di Nicolantonio, M. Martini, and F. Molinari Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 2008 5705 5712
29. G. Masi, F. Loupakis, and L. Salvatore Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial Lancet Oncol 11 2010 845 852
30. S.D. Richman, M.T. Seymour, and P. Chambers KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial J Clin Oncol 27 2009 5931 5937
31. G. Hutchins, K. Southward, and K. Handley Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer J Clin Oncol 29 2011 1261 1270
32. W. De Roock, B. Claes, and D. Bernasconi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
33. K.S. Smalley, M. Xiao, and J. Villanueva CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations Oncogene 28 2009 85 94
34. P.G. Gavin, L.H. Colangelo, and D. Fumagalli Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value Clin Cancer Res 18 2012 6531 6541
35. A.I. Phipps, D.D. Buchanan, and K.W. Makar BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics Cancer Epidemiol Biomarkers Prev 21 2012 1792 1798